ClinicalTrials.gg
Not yet recruitingNCT06955182Updated May 2, 2025

Dynamic Hot Spring Hydrotherapy for Gait Disorders and Balance Function Recovery After Stroke

An interventional study of Dynamic hot spring hydrotherapy intervention and Conventional rehabilitation intervention in Stroke, sponsored by The Second Affiliated Hospital of Kunming Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by The Second Affiliated Hospital of Kunming Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
293rd of 432
80 · median 169
Started
2025
with 71 others
No phase
264 of 613
123 open now
Primary completion
2026-01
later than 79 of 262 live
Registered
486th of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 293rd largest by planned enrollment of the 432 interventional ones that give a count, is one of 72 that started in 2025, is one of 264 with no phase, reaches primary completion later than 79 of the 262 other live ones, and was the 486th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

Our research aims to analyze and compare the improvement of various indicators of gait disorders and balance function before and after dynamic hot spring hydrotherapy and conventional exercise intervention, and clarify the therapeutic effect of dynamic hot spring hydrotherapy on gait disorders and balance function in stroke patients.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with cerebral infarction or cerebral hemorrhage who meet the diagnostic criteria for stroke of the Chinese Medical Association; (2) Initial stroke\<6 months, or last stroke event>6 months; (3) Age>=18 years old,\<85 years old (increased risk of VCI over 85 years old); (4) NIHSS>4, NIHSS\<26 points; (5) MRS score>=2 points; (6) complete CT or MRI; (7) No serious neurological or mental illness; Unconscious disorders, able to cooperate with relevant treatments; No severe cognitive impairment (>=15 points); (8) Berg Balance Scale>40 points; (9) The patient or family member signs an form.

Exclusion criteria

Exclusion Criteria:

  • (1) Concurrent major diseases, such as heart, lung, liver, kidney and other organ diseases or failure; (2) There are for hydrotherapy such as acute infectious diseases, open skin wounds, and severe epilepsy; (3) There are other clinical issues that may affect the assessment results, such as low vision, fractures, vestibular diseases, etc; (4) There are other neurological disorders, such as multiple sclerosis, Parkinson's disease, etc; (5) Serious mental and psychological problems exist; (6) Malignant tumor patients; (7) Early pregnancy or high-risk pregnancy; (8) Serious alcohol abusers; (9) Patients with active bleeding, such as gastrointestinal bleeding, nosebleeds, and excessive menstruation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Sham comparator
    Conventional rehabilitation intervention

    Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training

    Other: Conventional rehabilitation intervention

  • Experimental
    Dynamic hot spring hydrotherapy intervention

    Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training

    Other: Dynamic hot spring hydrotherapy intervention

Interventions

  • OtherDynamic hot spring hydrotherapy intervention

    Under closed management, patients will receive 5 times a week, 20 minutes of routine rehabilitation and 20 minutes of hot spring water exercise each time: (1) 20 minutes of routine rehabilitation: including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); (2) 20 minute hot spring water balance walking function training

  • OtherConventional rehabilitation intervention

    Under closed management, patients will receive routine physical therapy for 40 minutes 5 times a week: 1) 20 minutes of routine rehabilitation, including routine muscle strength enhancement training, joint range of motion training, and neuropathological methods (Bobath method, proprioceptive neuromuscular facilitation technique, etc.); 2) 20 minute land balance walking function training

06

What researchers measure

Primary outcomes

  1. Timed Up and Go Test, (TUG)

    Timed Stand Up Walking Test (TUG) Assess gait based on the time required for the test subject to stand up from the chair, walk at a steady pace to the 3-meter mark, and then return to the chair to sit down. The evaluation results are as follows: \<10 seconds: Normal activity ability, low risk of falling. 10-14 seconds: There may be mild functional impairment, further evaluation is needed. \>14 seconds: The risk of falling significantly increases (such as in elderly people or Parkinson's disease patients). \>20 seconds: Prompt for severe mobility impairment, requiring intervention (such as in post-stroke patients).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  2. 10 Meter Walk Test, (10WMT)

    Individuals walk 10 meters and have participants conduct 3 trials at a comfortable walking speed, followed by 3 trials at the patient's fast walking speed. Measure the middle 6 meters, allowing for acceleration and deceleration. The timing starts when the toe of the current foot crosses the 2-meter mark; The timer ends when the toe of the current foot crosses the 8-meter mark; In units of s, accurate to two decimal places; Calculate the average for each walking speed. The actual speed is 6m divided by the recorded seconds to obtain the speed in m/s. The speed rating results are as follows: \<0.4m/s can be used for family walking 0.4-0.8m/s allows for limited community walking \>0.8m/s can be used for community walking If the test subject requires full assistance, a score of 0 should be recorded.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  3. Berg Balance Scale, BBS

    The BBS consists of 14 projects, including sitting to stand, standing independently, sitting independently, standing to sit, bed chair transfer, standing with closed eyes, standing with both feet together, extending the upper limbs in the standing position, picking up objects from the ground in the standing position, turning around to look back, turning around once, alternating steps with both feet, standing on one leg, etc. Each project is rated from 0 to 4 points based on the patient's completion status, with a total score of 56 points. The evaluation results are as follows: 41-56 points: Good balance function, low risk of falling 21-40 points: There is a certain degree of decline in balance function, and the risk of falling is moderate 0-20 points: Severe impairment of balance function, high risk of falling

    Time frame: From enrollment to the end of treatment at 2 weeks.

  4. Fugl-Meyer Balance Assessment,(FMA-B)

    The ability of the test subject to complete various balance test items, including unsupported sitting; Healthy side "spreading wings" reaction; The completion of the "spreading wings" reaction on the affected side, standing with support, standing without support, standing on the healthy side, and standing on the affected side will be scored. Each examination item will be scored on a scale of 0-2 points, with the highest score of 14 points and the lowest score of 0 points. If the score is less than 14 points, it indicates that the balance function is impaired. The lower the score, the more severe the balance dysfunction.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  5. Forced Vital Capacity, (FVC).

    Typically, adult males consume 3000\~5000ml, while females consume 2000\~4000 liters.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  6. FEV1

    The amount of gas exhaled in the first second is approximately 3179 ± 117mL for normal males and 2314 ± 48mL for females, starting from the maximum inhalation to the level of total lung volume.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  7. Maximum Voluntary Ventilation, (MVV)

    The general normal standard for pulmonary function MVV is: Male: (104+2.71)L/min; female sex: (82.5+2.17)L/min。

    Time frame: From enrollment to the end of treatment at 2 weeks.

  8. VO2

    The maximum amount of oxygen that the human body can absorb per unit time during exercise is usually measured in milliliters per minute (ml/min). VO2 reflects the cardiovascular function and aerobic exercise capacity of the human body, and is an important indicator for evaluating human endurance.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  9. oxygen consumption per kg body weight, (VO2/Kg)

    Oxygen consumption per unit weight (kg) per unit time. Expressed in VO2/kg. It is an indicator of an individual's athletic ability.The unit is mL/(kg · min).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  10. METS

    METs (metabolic equivalents) are indicators of energy expenditure during physical activity. 1 MET is equal to the oxygen consumption during sitting (approximately 3.5 mL/kg/min).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  11. Respiratory Quotient, (RQ)

    RQ refers to the ratio of carbon dioxide production to oxygen consumption in the body, and is commonly used to evaluate the energy metabolism of the body in different states. The numerical range of RQ is between 0.67 and 1.3.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  12. VE

    It is the amount of ventilation that maintains normal gas exchange in a resting state, equal to tidal volume multiplied by respiratory rate per minute.The unit is L/min.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  13. breathing reserve ratio

    BR=Maximum Ventilation Volume (MVV) - Minute Ventilation Volume during Maximum Exercise (VE).Normal respiratory reserve should be greater than 15L/min, indicating normal dynamic lung function levels in the body.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  14. Tidal Volume, (VT)

    VT is the amount of gas entering and leaving the lungs during each breath, reflecting the ventilation function of the lungs. The normal range for adults is about 6-8 milliliters per kilogram of body weight.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  15. Heart Rate, (HR)

    Heart rate is an important indicator of the human cardiovascular system, which reflects the functional status of the heart. HR can refer to instantaneous heart rate, measured in beats per minute.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  16. VO2/WR

    Under normal physiological conditions, there is a linear relationship between VO2 and the power of the human body to do work, commonly expressed as VO2/WR, with the unit of m/(min · W). The normal value is 8.4\~11ml/(min · W). Decreased VO2/WR often indicates impaired oxygen delivery.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  17. The oxygen pulse (VO2/HR)

    The oxygen pulse is calculated by dividing VO2 by the heart rate at the same time. It is the amount of oxygen taken into the lung blood during one heart beat, which is equal to the product of the output per beat and the arterial mixed venous oxygen content difference \[C (a-v) O2\]. Its unit is ml/kg/min.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  18. VO2@AT

    It refers to the oxygen uptake at the anaerobic threshold (AT). The normal value of peakVO2 is usually greater than 40%, which is equivalent to 50%\~65% peakVO2.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  19. PetCO2

    It refers to the pressure value of carbon dioxide in the exhaled gas at the end of exhalation. By monitoring PetCO2, the condition of lung ventilation and blood flow can be reflected. The normal value of PetCO2 (end tidal carbon dioxide partial pressure) is 35-45 mmHg.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  20. PetO2

    It reflects the oxygen partial pressure in the alveolar gas at the end of exhalation, and the normal range of PetO2 is 95-100mmHg

    Time frame: From enrollment to the end of treatment at 2 weeks.

  21. VE/VO2

    VE/VO2 refers to the ratio of minute ventilation to minute oxygen consumption, which is normally between 25-35.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  22. VE/VCO2

    VE/VCO2 refers to the ratio of minute ventilation to minute carbon dioxide emissions, with a normal range of 30-40.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  23. SpO2

    SpO2 refers to pulse oximetry, and the normal range of SpO ₂ for normal adults in a calm breathing state at sea level is 95% -100%.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  24. HR_1_minute

    It usually refers to the number of heartbeats counted within one minute, with a focus on specific heart rate values per minute. Under normal circumstances, the heart rate of adults in a quiet state is generally 60-100 beats per minute.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  25. P Syst

    It refers to the pressure exerted by blood on the walls of blood vessels during cardiac contraction, at which the ventricles pump blood into the aorta, causing the pressure inside the aorta to rise to its highest value, usually measured in mmHg (millimeter of mercury). The normal range of systolic blood pressure for normal adults in a quiet state is usually 90-139mmHg.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  26. P Diast

    It is the pressure exerted on the blood vessel walls during diastole, when the ventricles are in a filled state and the pressure inside the aorta drops to its lowest value. The normal range of diastolic blood pressure for normal adults in a quiet state is generally 60-89mmHg.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  27. Step Length

    The horizontal distance from the same foot following the ground to the opposite foot following the ground (left/right step lengths may be asymmetric).Its unit is meters.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  28. Stride Length

    The horizontal distance between two consecutive landings of the heel on the same side (one complete gait cycle).Its unit is meters.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  29. Step Width

    The lateral distance between the inner edges of both feet, reflecting walking stability.Its unit is meters.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  30. Cadence

    Steps per minute (steps/minute), typically around 100-120 steps for adults.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  31. Walking Speed

    The distance traveled per unit of time (in meters per second), which comprehensively reflects gait function.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  32. Stance Phase

    The proportion of time the foot is in contact with the ground (approximately 60% of the normal gait cycle).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  33. Swing Phase

    The proportion of time spent swinging the foot off the ground (usually around 40%).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  34. Double Support

    The time for both feet to touch the ground simultaneously (prolonged when the pace slows down).Its unit is seconds.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  35. Hip joint

    Sagittal flexion/extension (normal range of approximately 30 ° flexion to 10 ° extension).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  36. Knee joint

    Sagittal plane flexion (0 ° extension to 60 ° flexion swing phase).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  37. Ankle joint

    Sagittal dorsiflexion/plantarflexion (dorsiflexion when the foot touches the ground, plantarflexion during advancement).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  38. Pelvic movements

    Forward/backward tilt, internal and external rotation, lateral tilt.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  39. Ground Reaction Force (GRF)

    Measured by a force measuring platform, a typical bimodal curve (first peak ≈ 110% of body weight, second peak ≈ 120% of body weight).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  40. Joint Moments

    Reflecting the control of muscles and ligaments over joints (such as predicting the risk of osteoarthritis with knee adduction torque).The unit of it is N · m (Newton meters)

    Time frame: From enrollment to the end of treatment at 2 weeks.

  41. Power

    Joint work efficiency (peak power during ankle joint propulsion is key).The unit it is W.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  42. Symmetry Index

    The difference in step size and support phase time between the left and right sides (often asymmetric in stroke patients).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  43. Phase Coordination

    The temporal relationship between the swing phase and the support phase (which may be disrupted in Parkinson's disease patients).

    Time frame: From enrollment to the end of treatment at 2 weeks.

  44. Center of gravity position

    It refers to the projection position of the center of gravity on the horizontal plane when the human body is standing quietly. By using pressure tablets and other devices, the front, back, left, and right positions of the center of gravity can be measured, reflecting the body's balance state under static conditions. Under normal circumstances, the center of gravity is relatively stable and within the range of the area supported by both feet.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  45. Center of gravity swing amplitude

    It refers to the maximum distance that the center of gravity deviates from the center position within a certain period of time. The smaller the swing amplitude, the better the static balance ability. Generally measured in millimeters (mm), when healthy adults stand quietly, the amplitude of their center of gravity swing back and forth is usually around 10-20mm, and the amplitude of left and right swing is relatively small.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  46. Center of gravity swing frequency

    It refers to the number of times the center of gravity swings per unit time. The lower the frequency, the stronger the static balance control capability. When a normal adult stands quietly, the frequency of center of gravity swing is generally between 0.5-2 times per second.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  47. Walking stability

    It is evaluated by analyzing the step characteristics during walking, including step length, stride length, step frequency, bipedal support time, single foot support time, and other parameters. For example, if the stride is uniform, the stride is stable, the stride frequency is moderate, and the ratio of foot support time to single foot support time is reasonable, it indicates good dynamic balance ability during walking. When adults walk normally, the stride length is about 50-80cm, and the step frequency is around 90-120 steps per minute.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  48. Posture transition ability

    It measures the stability and coordination during the transition from one posture to another (such as sitting to standing, standing to walking, etc.). The evaluation indicators include conversion time, accuracy of center of gravity shift, and whether additional support or auxiliary movements are needed. Healthy individuals complete posture transitions quickly and smoothly, with a smooth shift of center of gravity, typically without the need for external force or excessive adjustment movements.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  49. Disturbance response ability

    The ability of the human body to restore balance through its own balance adjustment mechanism when subjected to external disturbances such as sudden thrust, tension, or ground shaking. The relevant parameters include reaction time, maximum offset distance, and time to restore balance. Rapid response, ability to control the body's center of gravity within a small deviation range and quickly restore balance, indicate good disturbance response ability.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  50. Visual dependence level

    It is evaluated by comparing the balance test results between open and closed eye states. If the balance function significantly decreases after closing the eyes, it indicates a high degree of dependence on visual information; On the contrary, if there is not much difference in balance performance between opening and closing the eyes, it indicates that other balance regulation mechanisms such as proprioception have played a good role. For example, in the test of standing on one foot with closed eyes, the ability to stand for a longer period of time when the eyes are open is significantly reduced, indicating that vision plays an important role in maintaining balance in this posture.

    Time frame: From enrollment to the end of treatment at 2 weeks.

  51. Muscle activity pattern

    Using techniques such as surface electromyography to record the activation sequence, intensity, and duration of different muscles during balance tasks. Normal balance control requires multiple groups of muscles to work together, and whether the muscle activity pattern is normal or not can reflect the nervous system's ability to control muscles and the coordination and cooperation between muscles. For example, when maintaining balance in a standing position, the calf muscles, hip muscles, and back muscles will contract and relax in a timely manner according to changes in the body's center of gravity to maintain stability.

    Time frame: From enrollment to the end of treatment at 2 weeks.

Secondary outcomes

  1. anxiety

    Beck Anxiety Inventory Scoring is based on the severity of anxiety symptoms, and the total score is calculated by adding up each result. Scores 15-25 indicate mild anxiety, 26-35 indicate moderate anxiety, and scores above 36 indicate severe anxiety.

    Time frame: From enrollment to the end of treatment at 2 weeks

  2. sleep quality

    Pittsburgh Sleep Quality Index (PSQI) According to the various indicators of sleep quality, the frequency is divided into 0-5 points: good sleep quality, 6-10 points: decent sleep quality, 11-15 points: average sleep quality, 16-21 points: poor sleep quality.

    Time frame: From enrollment to the end of treatment at 2 weeks

  3. Self efficacy

    ABC Balanced Confidence Scale Based on the confidence level of each item, ranging from 0% (no confidence) to 100% (completely confident), the total score is taken as the average of all items. ≥ 80%: Good balance and confidence, low risk of falling; 50%\~80%: moderate risk; \<50%: High risk, requiring intervention.

    Time frame: From enrollment to the end of treatment at 2 weeks

  4. Neurotransmitters and Cytokines

    β - endorphin, tumor necrosis factor - α (TNF - α), and interleukin-6 (IL-6)

    Time frame: From enrollment to the end of treatment at 2 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Jan 2026, 8 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 8 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 2, 2025
StartEst.
May 2025
Primary completionEst.
Jan 20, 2026
CompletionEst.
Mar 30, 2026
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06955182
Lead sponsor
The Second Affiliated Hospital of Kunming Medical University
Responsible party
Liqing Yao (Department of rehabilitation medicine, the Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University) — Principal investigator
First posted
May 2, 2025
Start date
May 2025 (estimated)
Primary completion
Jan 20, 2026 (estimated)
Completion
Mar 30, 2026 (estimated)
Last update
May 2, 2025

Study contacts

Liqing Yao
Contact
yaoliqing98731@163.com
+8613529202383

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion